LifeMine secures $263 million in funding for its new drug development efforts, including a previously undisclosed $75 million Series D round. This capital aims to advance therapies for organ transplant patients and autoimmune conditions.

LifeMine announced a funding mix of new capital and a previously undisclosed $75 million Series D round. This funding will help advance their calcineurin inhibitor, LIFE-001, for organ transplant recipients. The company aims to complete a Phase 1 study and prepare for a Phase 2 study. CEO Greg Verdine is optimistic about the potential impact on patient care.